Clinical likelihood of sporadic primary EGFR T790M Mutation in EGFR-mutant Lung Cancer

Clinical Lung Cancer

Volumn 16, Issue 1, 2015, Pages 46-50

  Lee, Youngjoo ^a   Lee, Geon Kook ^a   Hwang, Jung Ah ^a   Yun, Tak ^a   Kim, Heung Tae ^a   Lee, Jin Soo ^a  

^a National Cancer Center   (South Korea)

Author keywords

Drug resistance; Drug sensitivity; EGFR mutation; EGFR tyrosine kinase inhibitor; Non small cell lung cancer; Sequencing

Indexed keywords

ANTINEOPLASTIC METAL COMPLEX; CYTOTOXIC AGENT; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; GEMCITABINE; PEMETREXED; PLATINUM; PROTEIN TYROSINE KINASE INHIBITOR; TAXANE DERIVATIVE; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR;

ADULT; ADVANCED CANCER; AGED; BONE METASTASIS; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PALLIATIVE THERAPY; CANCER STAGING; CLINICAL ARTICLE; CLINICAL FEATURE; CONFERENCE PAPER; CONTROLLED STUDY; DNA DETERMINATION; DRUG EFFICACY; EXON; FEMALE; GENE FREQUENCY; GENE MUTATION; GENOTYPE; HISTOLOGY; HUMAN; LIVER METASTASIS; LUNG CANCER; LUNG METASTASIS; MALE; MASS SPECTROMETRY; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; SMOKING; TREATMENT RESPONSE; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; GENETICS; LUNG NEOPLASMS; MORTALITY; MUTATION; PATHOLOGY; SECONDARY; STATISTICAL MODEL; SURVIVAL; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; DNA; FEMALE; GENOTYPE; HUMANS; LIKELIHOOD FUNCTIONS; LUNG NEOPLASMS; MALE; MASS SPECTROMETRY; MUTATION; NEOPLASM STAGING; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84927578869     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2014.09.002     Document Type: Conference Paper

References (20)

1. C. Roche Lestienne, V. Soenen Cornu, and N. Grardel Duflos Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment Blood 100 2002 1014 1018
2. S. Misale, R. Yaeger, and S. Hobor Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer Nature 486 2012 532 536
3. L.A. Diaz, R.T. Williams, and J. Wu The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers Nature 486 2012 537 540
4. S.G. Willis, T. Lange, and S. Demehri High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy Blood 106 2005 2128 2137
5. T.J. Lynch, D.W. Bell, and R. Sordella Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 2004 2129 2139
6. H.A. Yu, M.E. Arcila, and N. Rekhtman Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers Clin Cancer Res 19 2013 2240 2247
7. J. Shih, C. Gow, and P. Yang EGFR mutation conferring primary resistance to gefitinib in non-small-cell lung cancer N Engl J Med 353 2005 207 208
8. M. Inukai, S. Toyooka, and S. Ito Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer Cancer Res 66 2006 7854 7858
9. S. Maheswaran, L.V. Sequist, and S. Nagrath Detection of mutations in EGFR in circulating lung-cancer cells N Engl J Med 359 2008 366 377
10. T. Tanaka, M. Matsuoka, and A. Sutani Frequency of and variables associated with the EGFR mutation and its subtypes Int J Cancer 126 2010 651 655
11. M. Fukuoka, Y. Wu, and S. Thongprasert Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS) J Clin Oncol 29 2011 2866 2874
12. K. Su, H. Chen, and K. Li Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer J Clin Oncol 30 2012 433 440
13. Y. Fujita, K. Suda, and H. Kimura Highly sensitive detection of EGFR T790M mutation using colony hybridization predicts favorable prognosis of patients with lung cancer harboring activating EGFR mutation J Thorac Oncol 7 2012 1640 1644
14. C. Costa, M.A. Molina, and A. Drozdowskyj The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-Mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial Clin Cancer Res 20 2014 2001 2010
15. Y. Lee, G.K. Lee, and Y.S. Lee Clinical outcome according to the level of preexisting epidermal growth factor receptor T790M mutation in patients with lung cancer harboring sensitive epidermal growth factor receptor mutations Cancer 120 2014 2090 2098
16. A. Gazdar, L. Robinson, and D. Oliver Hereditary lung cancer syndrome targets never smokers with germline EGFR gene T790M mutations J Thorac Oncol 9 2014 456 463
17. D.H. Lee, G.K. Lee, and S. Kong Epidermal growth factor receptor status in anaplastic thyroid carcinoma J Clin Pathol 60 2007 881 884
18. E.A. Eisenhauer, P. Therasse, and J. Bogaerts New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 2009 228 247
19. G.R. Oxnard, M.E. Arcila, and C.S. Sima Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation Clin Cancer Res 17 2011 1616 1622
20. A. Hata, N. Katakami, and H. Yoshioka Rebiopsy of non-small cell lung cancer patients with acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor: Comparison between T790M mutation-positive and mutation-negative populations Cancer 119 2013 4325 4332